If retatrutide gains adult approval in 2026 or 2027 (Phase 3 results from the TRIUMPH program are expected in 2025 to 2026), an adolescent trial could begin enrollment by 2028 at the earliest, with results by 2030
Specifically, ICER indicated a benchmark annual price range for semaglutide of between $7,500 to $9,800 would make the product cost-effective
You get less flight time this way but it might be worth the trade off to you
Should GLP-1 therapy be stopped if gallstones are found
Semaglutide is contraindicated in patients with a personal or family history of certain types of thyroid cancer, specifically thyroid C-cell tumors such as medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
We offering monopoly-based Pharma franchise opportunities and a wide range of WHO-GMP certified medicines